Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ELDN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tegoprubart | Kidney Transplant Rejection | Phase 3 · NCT07835581 | Not yet recruiting |
| AT-1501 IV Infusion | Brittle Type 1 Diabetes Mellitus | Phase 1/2 · NCT05480657 | Withdrawn |
| Islet transplantation with Tegoprubart… | Type 1 Diabetes Mellitus | Phase 1/2 · NCT06305286 | Active not recruiting |
| Isolated cadaveric islet cells | Brittle Type 1 Diabetes Mellitus | Phase 1/2 · NCT05480657 | Withdrawn |
| Siplizumab | Kidney Failure | Early Phase 1 · NCT06972069 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not ELDN's own candidates): Tacrolimus Extended-Release.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ELDN holds $69.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.8M/quarter from operations, an estimated runway of 10 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 84 · High
Our financial condition raises substantial doubt as to our ability to continue as a going concern if we are unable to raise additional financing to fund our operations.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELDN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BVF PARTNERS L P/IL 10% owner · +1.14M options |
Insider | 8,655,393 | 10.25% | 2026-09-30 |
| Matthew D. Perry | Institution (13G, 5%+) | 4,762,691 | 5.64% | 2025-11-19 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,380,857 | 5.19% | 2026-03-31 |
| David-Alexandre C Gros Chief Executive Officer, Director · +1.68M options |
Insider | 168,663 | 0.20% | 2026-07-31 |
| Steven Perrin President, Director · +1.11M options |
Insider | 81,215 | 0.10% | 2026-07-31 |
| Keith Katkin Director · +77,175 options |
Insider | 8,575 | 0.01% | 2026-01-10 |
| Allan Kirk Director · +30,870 options |
Insider | 3,430 | 0.00% | 2026-01-10 |
| Jan Hillson Director · +30,870 options |
Insider | 3,430 | 0.00% | 2026-01-10 |
| James A. Jr. Robinson Director · +30,870 options |
Insider | 3,430 | 0.00% | 2026-01-10 |
| June Lee Director · +30,870 options |
Insider | 3,430 | 0.00% | 2026-01-10 |
| John S. McBride Director · +30,870 options |
Insider | 3,430 | 0.00% | 2026-01-10 |
Share count 84,459,713 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELDN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →